These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30631096)

  • 1. Transthyretin Aggregation Pathway toward the Formation of Distinct Cytotoxic Oligomers.
    Dasari AKR; Hughes RM; Wi S; Hung I; Gan Z; Kelly JW; Lim KH
    Sci Rep; 2019 Jan; 9(1):33. PubMed ID: 30631096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxic Misfolded Transthyretin Oligomers with Different Molecular Conformations Formed through Distinct Oligomerization Pathways.
    Dasari AKR; Yi S; Coats MF; Wi S; Lim KH
    Biochemistry; 2022 Nov; 61(21):2358-2365. PubMed ID: 36219173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of the CD Loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway.
    Dasari AKR; Arreola J; Michael B; Griffin RG; Kelly JW; Lim KH
    Biochemistry; 2020 Jun; 59(25):2319-2327. PubMed ID: 32500705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic Mutations Induce Partial Structural Changes in the Native β-Sheet Structure of Transthyretin and Accelerate Aggregation.
    Lim KH; Dasari AKR; Ma R; Hung I; Gan Z; Kelly JW; Fitzgerald MC
    Biochemistry; 2017 Sep; 56(36):4808-4818. PubMed ID: 28820582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the interfacial regions in misfolded transthyretin oligomers.
    Dasari AKR; Coats MF; Ali AB; Lim KH
    Biochim Biophys Acta Proteins Proteom; 2024 Sep; 1872(5):141027. PubMed ID: 38796131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct annular oligomers captured along the assembly and disassembly pathways of transthyretin amyloid protofibrils.
    Pires RH; Karsai Á; Saraiva MJ; Damas AM; Kellermayer MS
    PLoS One; 2012; 7(9):e44992. PubMed ID: 22984597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
    Lashuel HA; Lai Z; Kelly JW
    Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial conformational changes of human transthyretin under partially denaturing conditions.
    Yang M; Lei M; Bruschweiler R; Huo S
    Biophys J; 2005 Jul; 89(1):433-43. PubMed ID: 15821170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Force spectroscopy reveals the presence of structurally modified dimers in transthyretin amyloid annular oligomers.
    Pires RH; Saraiva MJ; Damas AM; Kellermayer MS
    J Mol Recognit; 2017 Mar; 30(3):. PubMed ID: 27808434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture.
    Sörgjerd K; Klingstedt T; Lindgren M; Kågedal K; Hammarström P
    Biochem Biophys Res Commun; 2008 Dec; 377(4):1072-8. PubMed ID: 18983977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational Dynamics of an Amyloidogenic Intermediate of Transthyretin: Implications for Structural Remodeling and Amyloid Formation.
    Leach BI; Ferguson JA; Morgan G; Sun X; Kroon G; Oyen D; Dyson HJ; Wright PE
    J Mol Biol; 2024 Aug; 436(16):168673. PubMed ID: 38909653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.
    Jiang X; Smith CS; Petrassi HM; Hammarström P; White JT; Sacchettini JC; Kelly JW
    Biochemistry; 2001 Sep; 40(38):11442-52. PubMed ID: 11560492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD and Solid-State NMR Studies of Low-Order Oligomers of Transthyretin.
    Dasari AKR; Lim KH
    Methods Mol Biol; 2023; 2551():311-320. PubMed ID: 36310212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
    McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
    Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy.
    Lindgren M; Sörgjerd K; Hammarström P
    Biophys J; 2005 Jun; 88(6):4200-12. PubMed ID: 15764666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A transthyretin monomer intermediate undergoes local unfolding and transient interaction with oligomers in a kinetically concerted aggregation pathway.
    Sun X; Ferguson JA; Dyson HJ; Wright PE
    J Biol Chem; 2022 Aug; 298(8):102162. PubMed ID: 35724960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two distinct aggregation pathways in transthyretin misfolding and amyloid formation.
    Dasari AKR; Hung I; Gan Z; Lim KH
    Biochim Biophys Acta Proteins Proteom; 2019 Mar; 1867(3):344-349. PubMed ID: 30366153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transthyretin variants with improved inhibition of β-amyloid aggregation.
    Mangrolia P; Yang DT; Murphy RM
    Protein Eng Des Sel; 2016 Jun; 29(6):209-218. PubMed ID: 27099354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why is Leu55-->Pro55 transthyretin variant the most amyloidogenic: insights from molecular dynamics simulations of transthyretin monomers.
    Yang M; Lei M; Huo S
    Protein Sci; 2003 Jun; 12(6):1222-31. PubMed ID: 12761393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoscale structural characterization of transthyretin aggregates formed at different time points of protein aggregation using atomic force microscopy-infrared spectroscopy.
    Rodriguez A; Ali A; Holman AP; Dou T; Zhaliazka K; Kurouski D
    Protein Sci; 2023 Dec; 32(12):e4838. PubMed ID: 37967043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.